Cargando…
The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, air...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871391/ https://www.ncbi.nlm.nih.gov/pubmed/33557843 http://dx.doi.org/10.1186/s12931-021-01638-7 |
_version_ | 1783648999300923392 |
---|---|
author | van den Berg, Mariska P. M. Nijboer-Brinksma, Susan Bos, I. Sophie T. van den Berge, Maarten Lamb, David van Faassen, Martijn Kema, Ido P. Gosens, Reinoud Kistemaker, Loes E. M. |
author_facet | van den Berg, Mariska P. M. Nijboer-Brinksma, Susan Bos, I. Sophie T. van den Berge, Maarten Lamb, David van Faassen, Martijn Kema, Ido P. Gosens, Reinoud Kistemaker, Loes E. M. |
author_sort | van den Berg, Mariska P. M. |
collection | PubMed |
description | BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, airway hyperresponsiveness (AHR) and inflammation. In the current study, we evaluated the efficacy of the novel TRPA1 antagonist BI01305834 against AHR and inflammation in guinea-pig models of asthma. METHODS: First, a pilot study was performed in a guinea-pig model of allergic asthma to find the optimal dose of BI01305834. Next, the effect of BI01305834 on (1) AHR to inhaled histamine after the early and late asthmatic reaction (EAR and LAR), (2) magnitude of EAR and LAR and (3) airway inflammation was assessed. Precision-cut lung slices and trachea strips were used to investigate the bronchoprotective and bronchodilating-effect of BI01305834. Statistical evaluation of differences of in vivo data was performed using a Mann–Whitney U test or One-way nonparametric Kruskal–Wallis ANOVA, for ex vivo data One- or Two-way ANOVA was used, all with Dunnett’s post-hoc test where appropriate. RESULTS: A dose of 1 mg/kg BI01305834 was selected based on AHR and exposure data in blood samples from the pilot study. In the subsequent study, 1 mg/kg BI01305834 inhibited AHR after the EAR, and the development of EAR and LAR elicited by ovalbumin in ovalbumin-sensitized guinea pigs. BI01305834 did not inhibit allergen-induced total and differential cells in the lavage fluid and interleukin-13 gene expression in lung homogenates. Furthermore, BI01305834 was able to inhibit allergen and histamine-induced airway narrowing in guinea-pig lung slices, without affecting histamine release, and reverse allergen-induced bronchoconstriction in guinea-pig trachea strips. CONCLUSIONS: TRPA1 inhibition protects against AHR and the EAR and LAR in vivo and allergen and histamine-induced airway narrowing ex vivo, and reverses allergen-induced bronchoconstriction independently of inflammation. This effect was partially dependent upon histamine, suggesting a neuronal and possible non-neuronal role for TRPA1 in allergen-induced bronchoconstriction. |
format | Online Article Text |
id | pubmed-7871391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78713912021-02-09 The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs van den Berg, Mariska P. M. Nijboer-Brinksma, Susan Bos, I. Sophie T. van den Berge, Maarten Lamb, David van Faassen, Martijn Kema, Ido P. Gosens, Reinoud Kistemaker, Loes E. M. Respir Res Research BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, airway hyperresponsiveness (AHR) and inflammation. In the current study, we evaluated the efficacy of the novel TRPA1 antagonist BI01305834 against AHR and inflammation in guinea-pig models of asthma. METHODS: First, a pilot study was performed in a guinea-pig model of allergic asthma to find the optimal dose of BI01305834. Next, the effect of BI01305834 on (1) AHR to inhaled histamine after the early and late asthmatic reaction (EAR and LAR), (2) magnitude of EAR and LAR and (3) airway inflammation was assessed. Precision-cut lung slices and trachea strips were used to investigate the bronchoprotective and bronchodilating-effect of BI01305834. Statistical evaluation of differences of in vivo data was performed using a Mann–Whitney U test or One-way nonparametric Kruskal–Wallis ANOVA, for ex vivo data One- or Two-way ANOVA was used, all with Dunnett’s post-hoc test where appropriate. RESULTS: A dose of 1 mg/kg BI01305834 was selected based on AHR and exposure data in blood samples from the pilot study. In the subsequent study, 1 mg/kg BI01305834 inhibited AHR after the EAR, and the development of EAR and LAR elicited by ovalbumin in ovalbumin-sensitized guinea pigs. BI01305834 did not inhibit allergen-induced total and differential cells in the lavage fluid and interleukin-13 gene expression in lung homogenates. Furthermore, BI01305834 was able to inhibit allergen and histamine-induced airway narrowing in guinea-pig lung slices, without affecting histamine release, and reverse allergen-induced bronchoconstriction in guinea-pig trachea strips. CONCLUSIONS: TRPA1 inhibition protects against AHR and the EAR and LAR in vivo and allergen and histamine-induced airway narrowing ex vivo, and reverses allergen-induced bronchoconstriction independently of inflammation. This effect was partially dependent upon histamine, suggesting a neuronal and possible non-neuronal role for TRPA1 in allergen-induced bronchoconstriction. BioMed Central 2021-02-08 2021 /pmc/articles/PMC7871391/ /pubmed/33557843 http://dx.doi.org/10.1186/s12931-021-01638-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research van den Berg, Mariska P. M. Nijboer-Brinksma, Susan Bos, I. Sophie T. van den Berge, Maarten Lamb, David van Faassen, Martijn Kema, Ido P. Gosens, Reinoud Kistemaker, Loes E. M. The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title_full | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title_fullStr | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title_full_unstemmed | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title_short | The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
title_sort | novel trpa1 antagonist bi01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871391/ https://www.ncbi.nlm.nih.gov/pubmed/33557843 http://dx.doi.org/10.1186/s12931-021-01638-7 |
work_keys_str_mv | AT vandenbergmariskapm thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT nijboerbrinksmasusan thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT bosisophiet thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT vandenbergemaarten thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT lambdavid thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT vanfaassenmartijn thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT kemaidop thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT gosensreinoud thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT kistemakerloesem thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT vandenbergmariskapm noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT nijboerbrinksmasusan noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT bosisophiet noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT vandenbergemaarten noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT lambdavid noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT vanfaassenmartijn noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT kemaidop noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT gosensreinoud noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs AT kistemakerloesem noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs |